• 协议覆盖率亚洲、美国、日本的及马来西亚，已成定局促进HLX13在癌肿抗体聯合治療这个领域的全球最大可及性

可根据协议模板免责条款，复宏汉霖将管理HLX13的研发项目管理、产量同时商业楼运作化批售，并从交易价格价格中提升3.01000万澳元的隐性薪资，但其中31000万澳元为交易价格价格分期支付款款。看作欧洲仿制药与微生物学体有些相似药行业的官员者，山德士依然以“让更健康无法触及”为初心，得益于约1,300款产品的总共使用受惠欧洲9亿提高。我县复宏汉霖联手山德士，将有力借助其成长期的欧洲数据网络与微生物学体有些相似药商业楼运作化竞争优势，下载加速HLX13在欧洲新趋势微生物学体药市扬的可及性。

复宏汉霖施行监事、首席总裁施行官

朱俊搏士写出

复宏汉霖小说总裁商务接待快速发展官兼高级工程师总经理裁

曹平男士表达出来

HLX13是复宏汉霖自研怪物像药供水管的至关重要构成，其原研药伊匹木单抗（Yervoy^®）作欧洲首批CTLA-4抑制性剂，已在数个国家各地和各地应用，适应能力环境症分为共同纳武利尤单抗用作黑灰着色剂瘤、肝癌细胞癌等一品类适应能力环境症。复宏汉霖已勾勒了体化欧洲技术创新、药政注册账号及医学制作运营策划的平台，并打造了完全符合欧洲药品监督操作请求的分娩和效率操作制度，成功的驱动4款设备在在美国市厂应用面市。公司的将新一轮助推HLX13的欧洲制作应用程序，全力于联手合作方式朋友们为欧洲我们提供数据大多高效率可额外负担的调理预案。

 Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

• Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations

• Henlius to receive $31 million upfront, and up to $270 million in milestones

On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

Under the agreement, Henlius will be responsible for development, manufacturing and commercial supply of HLX13, and is eligible to receive up to a total of $301 million, including a $31 million upfront and additional milestone payments. As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of “pioneering access for patients” and has benefited over 900 million patients worldwide with approximately 1,300 products. This collaboration will leverage Sandoz’s established global network and commercialization expertise to accelerate the accessibility of HLX13 in mainstream biopharma markets.

“At Henlius, we remain deeply committed to delivering high-quality biologics to patients around the world,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “Our collaboration with Sandoz marks another important step toward enhancing the global accessibility of our therapies. We believe that putting patients at the core of our globalization strategy is key to fulfilling our vision of ‘Developed in China, Access for the World.’”

“We’re excited to join forces with Sandoz,” said Ping Cao, Chief Business Officer and Senior Vice President of Henlius. “By combining Henlius’ proven strengths in biologics R&D and manufacturing with extensive global reach and commercialization expertise of Sandoz, we aim to accelerate the worldwide expansion of HLX13 and bring advanced treatment options to more patients across key markets.”

HLX13 is a key component of Henlius’ self-developed biosimilar pipeline. Its reference product, Yervoy^®, the world’s first CTLA-4 inhibitor, has been approved in various countries and regions in combination with nivolumab for the treatment of melanoma and hepatocellular carcinoma, among other indications. Henlius has established an integrated global platform for R&D, regulatory registration, and clinical operations, backed by a manufacturing and quality management system that meets global regulatory standards. The company has successfully launched four products in markets beyond China. Henlius is committed to advancing the global development of HLX13 and working with partners to provide more high-quality, affordable treatment options for patients worldwide.

*Yervoy^® is a registered trademark of Bristol-Myers Squibb (US)